NYSEMKT: NBYNovabay Pharmaceuticals Inc Stock
$0.12+0.00 (+0%)
Updated May 17, 2024
NBY Price
$0.12
Fair Value Price
N/A
Market Cap
$4.50M
52 Week Low
$0.07
52 Week High
$1.28
P/E
-0.03x
P/B
28.14x
P/S
0.18x
PEG
N/A
Dividend Yield
N/A
Revenue
$14.23M
Earnings
-$11.12M
Gross Margin
54.5%
Operating Margin
-78.09%
Profit Margin
-130.3%
Debt to Equity
32.48
Operating Cash Flow
-$4M
Beta
0.73
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NBY Overview
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing products for the eye care market. The company is headquartered in Emeryville, California and currently employs 70 full-time employees. The firm focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. The company develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The firm's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NBY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NBY is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NBY is poor value based on its book value relative to its share price (28.14x), compared to the US Biotechnology industry average (6.01x)
P/B vs Industry Valuation
NBY is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NBY due diligence checks available for Premium users.
Be the first to know about important NBY news, forecast changes, insider trades & much more!
NBY News
Valuation
NBY price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.03x
Industry
8.47x
Market
30.97x
NBY price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
28.14x
Industry
6.01x
NBY is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NBY's financial health
Profit margin
Revenue
$2.6M
Net Income
-$3.2M
Profit Margin
-136.6%
NBY's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
NBY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$5.4M
Liabilities
$5.2M
Debt to equity
32.48
NBY's short-term liabilities ($3.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NBY's short-term assets ($3.59M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NBY's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NBY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.6M
Investing
$1.1M
Financing
-$597.0k
NBY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NBY vs Biotech Stocks
Novabay Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.